ClinGen Dosage Sensitivity Curation Page

See New Dosage Map New! The ClinGen Dosage Sensitivity curations and downloads that are available at this site are now also available at www.clinicalgenome.org. Click on the button to access Dosage Sensitivity in the context of ClinGen's other curated information, including Gene-Disease Validity and Clinical Actionability.

ARHGEF6

  • Curation Status: Complete

Location Information

Select assembly: (NC_000023.10) (NC_000023.11)
  • Haploinsufficiency score: 0
  • Strength of Evidence (disclaimer): No evidence for dosage pathogenicity

Haploinsufficiency phenotype comments:

There are no clear loss of function mutations reported for ARHGEF6. One paper (PMID: 11017088) reports a boy with intellectual disability who has an apparently balanced t(X;21) that has a breakpoint within intron 10 of ARHGEF6. The mother is a carrier and phenotypically normal, so it would be expected that her normal X is inactivated. However, normal mRNA was detected in the mother and ARHGEF6 does not escape X-inactivation. This paper also reports a family with X-linked intellectual disability and an intronic substitution (IVS1-11T>C). This appeared to cause skipping of exon 2 yielding an in-frame deletion in a subset of transcripts. It is not clear if this single exon deletion would lead to loss-of-function of this gene.

The loss-of-function and triplosensitivity ratings for genes on the X chromosome are made in the context of a male genome to account for the effects of hemizygous duplications or nullizygous deletions. In contrast, disruption of some genes on the X chromosome causes male lethality and the ratings of dosage sensitivity instead take into account the phenotype in female individuals. Factors that may affect the severity of phenotypes associated with X-linked disorders include the presence of variable copies of the X chromosome (i.e. 47,XXY or 45,X) and skewed X-inactivation in females.

  • Triplosensitivity score: 0
  • Strength of Evidence (disclaimer): No evidence for dosage pathogenicity

Triplosensitivity phenotype comment:

Focal duplications of ARHGEF6 have not been reported. Larger duplications including ARHGEF6 and other genes have been reported (PMID: 20861843).

The loss-of-function and triplosensitivity ratings for genes on the X chromosome are made in the context of a male genome to account for the effects of hemizygous duplications or nullizygous deletions. In contrast, disruption of some genes on the X chromosome causes male lethality and the ratings of dosage sensitivity instead take into account the phenotype in female individuals. Factors that may affect the severity of phenotypes associated with X-linked disorders include the presence of variable copies of the X chromosome (i.e. 47,XXY or 45,X) and skewed X-inactivation in females.